A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children
Cidofovir
Neoplasms+2
+ Neoplasms by Histologic Type
+ Neoplasms, Glandular and Epithelial
Treatment Study
Summary
Your child will be assigned randomly (like tossing a coin) to receive either cidofovir or placebo (an inactive substance). Neither you nor your doctor will know which your child is receiving. Your child will undergo a total of 6 bronchoscopic procedures, which involves placing a tube down your child's throat so that the warts can be seen and treated. The warts will be removed by laser or other procedures and the study drug injected. Study drug will be injected at the sites of all newly removed warts and warts which were removed during earlier study visits. This procedure will be performed every other week. Blood and urine tests will also be performed at this time. Your child will be under general anesthesia during each procedure and will be in the surgery unit for about 6 to 8 hours. Your child will also have to be seen by the doctor 2 days after the procedure. Your child will be followed for a total of 5 years to make sure he/she develops normally and to monitor any side effects of cidofovir. Follow-up visits will take place at Months 3, 6, and then once every 6 months through Year 5. If necessary, laser or other procedures will be performed at these visits to remove any warts.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.36 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 2 to 17 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: Your child may be eligible for this study if he/she: Has active laryngeal papillomatosis (warts in the throat) that requires 8 or more surgeries per year. Developed this infection before the age of 16. Is between the ages of 2 and 17 years with consent of parent or guardian. Exclusion Criteria: Your child will not be eligible for this study if he/she: Has a history of a prior malignancy (cancer), kidney disease, or immune system deficiency. Is HIV-positive. Is allergic to probenecid. Has received radiation therapy to the throat area or has received certain medications. Is pregnant or breast-feeding.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
NIAID/DMID/CASG Central Unit
Birmingham, United StatesOpen NIAID/DMID/CASG Central Unit in Google Maps